BLCO241220C22500
- 0.25
- -0.08-24.24%
Bausch + Lomb Corp. Newsroom
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue Eye Care Recycling Programs
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $26
Express News | Bausch + Lomb: Two new professional lutein dietary supplements will be launched.
Express News | Bausch Lomb has added a $0.4 billion loan to repay revolving loans.
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $24
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $23 to $26
Express News | Bausch + Lomb : H.c. Wainwright Raises Target Price to $23 From $22
Bausch + Lomb Corp. | 10-Q: Q3 2024 Earnings Report
Bausch + Lomb Swings to Quarterly Profit, Lifts Full-Year Revenue Target Range
Bausch + Lomb Corp. | 8-K: Bausch + Lomb Announces Third-Quarter 2024 Results
Bausch + Lomb Raises FY24 Revenue Guidance To $4.725B-$4.825B (Prior $4.7B-$4.8B)
Bausch + Lomb Adj. EPS Excluding Acquired IPR&D $0.17
Bausch & Lomb Q3 Sales $1.196B Beat $1.180B Estimate
Bausch + Lomb Announces Third-Quarter 2024 Results
Earnings Preview: BLCO to Report Financial Results Pre-market on October 30
$Bausch + Lomb Corp.(BLCO.US)$ is scheduled to release its financial results pre-market on October 30 ET. Earnings PreviewAnalysts estimate $Bausch + Lomb Corp.(BLCO.US)$ to post revenue of USD1.17B
Bausch + Lomb Q3 Report Likely to Focus on Potential Sale, Dry Eye Disease Drugs, RBC Says
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Raises Target Price to $23
Express News | Bausch + Lomb : RBC Raises Target Price to $23 From $20
Market Chatter: Banks, Equity Firms Vying to Fund Potential Bausch + Lomb Buyout Deal
'Banks, Private Credit Vie for $5 Billion Bausch + Lomb Financing' - Bloomberg